DK3402503T3 - Terapeutiske kombinationer af et antifolat og en btk-hæmmer - Google Patents
Terapeutiske kombinationer af et antifolat og en btk-hæmmer Download PDFInfo
- Publication number
- DK3402503T3 DK3402503T3 DK17701596.3T DK17701596T DK3402503T3 DK 3402503 T3 DK3402503 T3 DK 3402503T3 DK 17701596 T DK17701596 T DK 17701596T DK 3402503 T3 DK3402503 T3 DK 3402503T3
- Authority
- DK
- Denmark
- Prior art keywords
- antifolate
- btk inhibitor
- therapeutic combinations
- therapeutic
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662278374P | 2016-01-13 | 2016-01-13 | |
| US201662371626P | 2016-08-05 | 2016-08-05 | |
| PCT/IB2017/050198 WO2017122175A1 (en) | 2016-01-13 | 2017-01-13 | Therapeutic combinations of an antifolate and a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3402503T3 true DK3402503T3 (da) | 2020-12-21 |
Family
ID=57890871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17701596.3T DK3402503T3 (da) | 2016-01-13 | 2017-01-13 | Terapeutiske kombinationer af et antifolat og en btk-hæmmer |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190008869A1 (da) |
| EP (1) | EP3402503B1 (da) |
| DK (1) | DK3402503T3 (da) |
| ES (1) | ES2839408T3 (da) |
| HU (1) | HUE052893T2 (da) |
| PL (1) | PL3402503T3 (da) |
| WO (1) | WO2017122175A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3372615A1 (en) * | 2017-03-06 | 2018-09-12 | Merck Patent GmbH | Composition comprising avelumab |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2512572A (en) | 1950-06-20 | Substituted pteridines and method | ||
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
| EP1210372B1 (en) | 1999-07-29 | 2008-01-23 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| WO2003085107A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules à génome modifié |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| SG132683A1 (en) | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
| CN105315373B (zh) | 2005-05-09 | 2018-11-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
| KR101562580B1 (ko) | 2007-06-18 | 2015-10-22 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US7894450B2 (en) | 2007-12-31 | 2011-02-22 | Nortel Network, Ltd. | Implementation of VPNs over a link state protocol controlled ethernet network |
| SG10201605472WA (en) | 2008-01-04 | 2016-09-29 | Intellikine Llc | Certain Chemical Entities, Compositions And Methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP2011526299A (ja) | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス， インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
| SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| LT2975042T (lt) | 2010-06-23 | 2019-01-25 | Hanmi Science Co., Ltd. | Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui |
| US9783578B2 (en) | 2010-06-25 | 2017-10-10 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2603081B1 (en) | 2010-08-10 | 2016-10-05 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
| US8529202B2 (en) | 2010-10-12 | 2013-09-10 | General Electric Company | System and method for turbine compartment ventilation |
| CA2760174A1 (en) | 2011-12-01 | 2013-06-01 | Pharmascience Inc. | Protein kinase inhibitors and uses thereof |
| CN103582643B (zh) | 2011-04-04 | 2016-06-15 | 弗马塞斯有限公司 | 蛋白激酶抑制剂 |
| ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| DK3689878T3 (da) | 2011-07-19 | 2021-11-08 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer |
| US20140155406A1 (en) | 2011-07-19 | 2014-06-05 | Petrus Antonius De Adrianus Man | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk inhibitors |
| BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
| PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
| RU2750538C2 (ru) | 2011-11-29 | 2021-06-29 | Оно Фармасьютикал Ко., Лтд. | Гидрохлорид производного пуринона |
| CN104159911A (zh) | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| WO2013144704A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR101793807B1 (ko) | 2013-04-25 | 2017-11-03 | 베이진 엘티디 | 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물 |
| US20150005277A1 (en) | 2013-06-28 | 2015-01-01 | Beigene, Ltd. | Protein Kinase Inhibitors and Uses Thereof |
| HUP1300432A2 (hu) | 2013-07-10 | 2015-01-28 | Tamas Kardos | Downhill kerékpár szerkezet javított felfüggesztéssel |
| EP3041828B1 (en) | 2013-09-06 | 2018-05-23 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| CA2922607C (en) | 2013-09-06 | 2022-08-30 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
| WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
| EP4130044A1 (en) | 2013-09-13 | 2023-02-08 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| TWI617309B (zh) * | 2013-10-25 | 2018-03-11 | 製藥公司 | 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法 |
| WO2015110923A2 (en) * | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
-
2017
- 2017-01-13 HU HUE17701596A patent/HUE052893T2/hu unknown
- 2017-01-13 DK DK17701596.3T patent/DK3402503T3/da active
- 2017-01-13 US US16/070,089 patent/US20190008869A1/en not_active Abandoned
- 2017-01-13 ES ES17701596T patent/ES2839408T3/es active Active
- 2017-01-13 EP EP17701596.3A patent/EP3402503B1/en active Active
- 2017-01-13 PL PL17701596T patent/PL3402503T3/pl unknown
- 2017-01-13 WO PCT/IB2017/050198 patent/WO2017122175A1/en active Application Filing
-
2019
- 2019-07-03 US US16/502,545 patent/US20190374543A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190008869A1 (en) | 2019-01-10 |
| WO2017122175A1 (en) | 2017-07-20 |
| PL3402503T3 (pl) | 2021-04-19 |
| EP3402503A1 (en) | 2018-11-21 |
| ES2839408T3 (es) | 2021-07-05 |
| EP3402503B1 (en) | 2020-10-21 |
| US20190374543A1 (en) | 2019-12-12 |
| HUE052893T2 (hu) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3179991T3 (da) | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor | |
| DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
| DK3270915T3 (da) | Kombineret behandling med en TLR7-agonist og en HBV-kapsidsamlingsinhibitor | |
| DK3618842T3 (da) | Kombination af en celleterapi og en immunomodulerende forbindelse | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3426859T3 (da) | Gipspanel, anvendelse af et sådant panel og fremgangsmåde til fremstilling af et sådant panel | |
| DK3452485T3 (da) | Arginasehæmmere og deres terapeutiske anvendelser | |
| DK3262046T3 (da) | Salte af pi3k-inhibitor og fremgangsmåder til fremstilling deraf | |
| DK2937422T3 (da) | Fremgangsmåde og et kit til ikke-invasiv detektering af patogene genmutationer for fosterdøvhed | |
| DK3227310T3 (da) | Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer | |
| DK3350201T3 (da) | Manipulerede fytaser og fremgangsmåder til anvendelse af samme | |
| DK3122359T3 (da) | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer | |
| DK3629838T3 (da) | Bærbar stol og fremgangsmåder til fremstilling af en bærbar stol | |
| DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
| MA46783A (fr) | Polythérapie de type thérapie cellulaire t et inhibiteur de btk | |
| DK3487505T3 (da) | Indgivelse og dosering af diaminophenothiaziner | |
| DK3302549T3 (da) | Kombinationsbehandling af et anti-CD20-antistof med en Bcl-2-inhibitor og en MDM2-inhibitor | |
| DK3353175T3 (da) | Salte og faste former af et monobactam-antibiotikum | |
| DK3099800T3 (da) | Ekspression og oprensning af crm197 og beslægtede proteiner | |
| DK3282373T3 (da) | Validering og integration af samarbejdningsregnearksdata | |
| DK3413897T3 (da) | Fremgangsmåder til behandling og profylakse af hiv og aids | |
| DK3278803T3 (da) | Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor | |
| DK3362399T4 (da) | Arrangement af en styring og et mobilt styringsmodul | |
| DK3099713T3 (da) | Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne | |
| DK3630772T3 (da) | Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere |